SW033291
Based on 8 publication(s) in Google Scholar
SW033291 is a potent and high-affinity inhibitor of 15-PGDH with a Ki of 0.1 nM. SW033291 increases prostaglandin PGE2 levels in bone marrow and other tissues. SW033291 also promotes tissue regeneration.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.36%
- No. CAS: 459147-39-8
- Fòrmula: C21H20N2OS3
- Peso molecular:412.59
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-123548
ML14815-PGDH Inhibitor -
HY-101952
Prostaglandin E2Prostaglandin Receptor Agonist -
HY-10219
RapamycinmTOR Inhibitor -
HY-10182
LaduviglusibGSK-3 Inhibitor -
HY-13226
GalunisertibTGFβRI Inhibitor -
HY-15371
ForskolinAdenylate Cyclase Activator -
HY-B0764
Bucladesine sodiumcAMP Analog -
HY-112693
H-151STING Antagonist -
HY-14649
Retinoic acidRAR Agonist -
HY-N0180
18β-Glycyrrhetinic acidEndogenous Metabolite -
HY-12874
CASINGTPase Cdc42 Inhibitor -
HY-10221
VorinostatHDAC Inhibitor
Publications Citing Use of MedChemExpress (MCE) SW033291
More- Adv Sci (Weinh). 2026 Jul 7:e20994.
- Stem Cell Res Ther. 2020 Feb 21;11(1):76. [Abstract]
- J Invest Dermatol. 2022 Mar;142(3 Pt A):653-661.e2. [Abstract]
- Int Immunopharmacol. 2026 Jan 1;168(Pt 1):115700. [Abstract]
- Int J Mol Sci. 2023 Mar 7;24(6):5111. [Abstract]
- Bioorg Chem. 2023 Aug:137:106646. [Abstract]
- Cell Signal. 2023 Aug:108:110707. [Abstract]
- J Biochem. 2023 Mar 31;173(4):293-305. [Abstract]
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Cell Imaging/Staining
-
RT-PCR
-
WB
-
IHC
Actividad biológica
Descripciòn
IC50 & Target
Ki: 0.1 nM (15-PGDH)[1]
In Vitro
Treating cells with SW033291 decreases cellular 15-PGDH enzyme activity by 85%. SW033291 inhibition of 15-PGDH was non-competitive versus PGE2 over concentrations up to 40 μM PGE2. Treatment of A549 cells with SW033291 increases PGE2 levels by 3.5-fold at 500 nM, with an EC50 50 at approximately 75 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J mice[1]
-
Dosage:10 mg/kg
-
Administration:Intraperitoneal injection; twice daily; for 3 days ( for 5 doses)
-
Result:Showed significant benefits, including a doubling of peripheral neutrophil counts, a 65% increase in marrow SKL cells, and a 71% increase in marrow SLAM cells.
Chemical Information
-
No. CAS 459147-39-8
-
Appearance Solid
-
Peso molecular 412.59
-
Fòrmula C21H20N2OS3
-
Color Light yellow to yellow
-
SMILES
NC1=C(S(CCCC)=O)SC2=NC(C3=CC=CS3)=CC(C4=CC=CC=C4)=C21
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
-
Stem Cell Res Ther
Effects of SW033291 on the myogenesis of muscle-derived stem cells and muscle regeneration. [Abstract]2020 Feb 21;11(1):76. PMID: 32085799
SW033291 purchased from MedChemExpress. Usage Cited in: Stem Cell Res Ther. 2020 Feb 21;11(1):76. [Abstract]
Cell viability of MDSCs in GM under different concentration of SW033291 (20, 50, 100, 500, 1000 nM) treatment.
SW033291 purchased from MedChemExpress. Usage Cited in: Stem Cell Res Ther. 2020 Feb 21;11(1):76. [Abstract]
LIVE/DEAD staining of MDSCs cultured in DM and GM treated with different concentration of SW033291 (20, 50, 100, 500, 1000 nM) on day 1 and day 3.
SW033291 purchased from MedChemExpress. Usage Cited in: Stem Cell Res Ther. 2020 Feb 21;11(1):76. [Abstract]
qPCR analysis of the expression of myogenic differentiation-related genes in MDSCs cultured in DM (top row) and GM (bottom row) under 100 nM SW033291 treatment on days 3 and 7.
SW033291 purchased from MedChemExpress. Usage Cited in: Stem Cell Res Ther. 2020 Feb 21;11(1):76. [Abstract]
Western blot analysis of the protein expression of myogenic markers in MDSCs cultured in DM and GM under 100 nM SW033291 treatment on day 3.
SW033291 purchased from MedChemExpress. Usage Cited in: Stem Cell Res Ther. 2020 Feb 21;11(1):76. [Abstract]
Cellular immunochemistry image of MHC in MDSCs cultured in DM and GM under 100 nM SW033291 treatment on day 7.
-
J Invest Dermatol
Activin A Sustains the Metastatic Phenotype of Tumor-Associated Macrophages and Is a Prognostic Marker in Human Cutaneous Melanoma. [Abstract]2022 Mar;142(3 Pt A):653-661.e2. PMID: 34499901 -
Int Immunopharmacol
Adoptive transfer of TregIL-33 cells ameliorates acute graft-versus-host disease by regulating the HPGD/PGE2 pathway. [Abstract]2026 Jan 1;168(Pt 1):115700. PMID: 41187423 -
Int J Mol Sci
The Enzyme 15-Hydroxyprostaglandin Dehydrogenase Inhibits a Shift to the Mesenchymal Pattern of Trophoblasts and Decidual Stromal Cells Accompanied by Prostaglandin Transporter in Preeclampsia. [Abstract]2023 Mar 7;24(6):5111. PMID: 36982197 -
Bioorg Chem
15-Hydroxyprostaglandin dehydrogenase inhibitor SW033291 ameliorates hepatic abnormal lipid metabolism, ER stress, and inflammation through PGE2/EP4 in T2DM mice. [Abstract]2023 Aug:137:106646. PMID: 37285764 -
Cell Signal
The 15-hydroxyprostaglandin dehydrogenase inhibitor SW033291 ameliorates abnormal hepatic glucose metabolism through PGE2-EP4 receptor-AKT signaling in a type 2 diabetes mellitus mouse model. [Abstract]2023 Aug:108:110707. PMID: 37164143 -
J Biochem
Identification and characterization of bioactive metabolites of 12-hydroxyheptadecatrienoic acid, a ligand for leukotriene B4 receptor 2. [Abstract]2023 Mar 31;173(4):293-305. PMID: 36539331
Solvente y solubilidad
In Vitro:
DMSO : 33.33 mg/mL (80.78 mM; ultrasonic and warming and heat to 70°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : 25 mg/mL (60.59 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (6.06 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (6.06 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (6.06 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (6.06 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (277 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol / DMSO | 1 mM | 2.4237 mL | 12.1186 mL | 24.2371 mL | 60.5928 mL |
| 5 mM | 0.4847 mL | 2.4237 mL | 4.8474 mL | 12.1186 mL | |
| 10 mM | 0.2424 mL | 1.2119 mL | 2.4237 mL | 6.0593 mL | |
| 15 mM | 0.1616 mL | 0.8079 mL | 1.6158 mL | 4.0395 mL | |
| 20 mM | 0.1212 mL | 0.6059 mL | 1.2119 mL | 3.0296 mL | |
| 25 mM | 0.0969 mL | 0.4847 mL | 0.9695 mL | 2.4237 mL | |
| 30 mM | 0.0808 mL | 0.4040 mL | 0.8079 mL | 2.0198 mL | |
| 40 mM | 0.0606 mL | 0.3030 mL | 0.6059 mL | 1.5148 mL | |
| 50 mM | 0.0485 mL | 0.2424 mL | 0.4847 mL | 1.2119 mL | |
| 60 mM | 0.0404 mL | 0.2020 mL | 0.4040 mL | 1.0099 mL | |
| DMSO | 80 mM | 0.0303 mL | 0.1515 mL | 0.3030 mL | 0.7574 mL |
SW033291 Related Classifications
HY-16968 Related Classifications
Powered by Bioz